Science Explorer Back to mapMap
Discussion
Institution · Agios Pharmaceuticals (United States)

Most cited papers from Agios Pharmaceuticals (United States)

Agios Pharmaceuticals (United States)

What are the most cited papers from Agios Pharmaceuticals (United States)?

The most cited paper from Agios Pharmaceuticals (United States) is "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate" (Lenny Dang, David W. White, Stefan Größ et al., 2009), with 4,209 citations. Next come "Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation" (2,793) and "Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization" (2,076).

Showing 50 of 60 papers. Every paper with more than 203 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Lenny Dang, David W. White, Stefan Größ et al. · Nature Open access 22 Nov 2009 4,209
2 Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation María E. Figueroa et al. · Cancer Cell Open access Dec 2010 2,793
3 Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization Abhishek Jha, Stanley Ching‐Cheng Huang, Alexey Sergushichev et al. · Immunity Open access Mar 2015 2,076
4 The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate Patrick S. Ward, Jay L. Patel, David R. Wise et al. · Cancer Cell Open access 22 Feb 2010 2,030
5 Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Richard Possemato et al. · Nature Open access 14 Jul 2011 1,755
6 Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Eytan M. Stein et al. · Blood Open access 6 Jun 2017 1,507
7 Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML Courtney Denton Dinardo et al. · New England Journal of Medicine Open access 2 Jun 2018 1,458
8 An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells Dan Rohle et al. · Science Open access 4 Apr 2013 1,179
9 Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Ghassan K. Abou‐Alfa et al. · The Lancet Oncology Open access 13 May 2020 1,117
10 Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer Krushna Chandra Patra, Qi Wang, Prashanth T. Bhaskar et al. · Cancer Cell Open access Aug 2013 879
11 Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis Dimitrios Anastasiou et al. · Nature Chemical Biology Open access 26 Aug 2012 842
12 Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation Fang Wang et al. · Science 4 Apr 2013 816
13 Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis Monika Bambousková et al. · Nature Open access Apr 2018 748
14 Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations Stefan Größ, Rob A. Cairns, Mark David Minden et al. · The Journal of Experimental Medicine Open access 8 Feb 2010 737
15 Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation Peppi Koivunen, Sung-Woo Lee, Christopher G. Duncan et al. · Nature Open access 14 Feb 2012 737
16 Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping Darrell R. Borger, Kenneth K. Tanabe, Kenneth C. Fan et al. · The Oncologist Open access 16 Dec 2011 728
17 Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism Wen Yi, Peter M. Clark, Daniel E. Mason et al. · Science Open access 23 Aug 2012 692
18 ESKAPEing the labyrinth of antibacterial discovery Rubén Tommasi, Dean G. Brown, Grant K. Walkup et al. · Nature Reviews Drug Discovery Review 3 Jul 2015 628
19 Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate Lukas Bunse et al. · Nature Medicine 6 Jul 2018 554
20 Unraveling the therapeutic potential of the Hedgehog pathway in cancer Dereck Dokyi Amakye, Zainab Jagani, Marion Dorsch · Nature Medicine Nov 2013 553
21 IDH mutations in cancer and progress toward development of targeted therapeutics Lenny Dang, Katharine E. Yen, Eyal C. Attar · Annals of Oncology Open access 22 Mar 2016 524
22 IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics Masato Sasaki et al. · Nature Open access 4 Jul 2012 514
23 Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation Andrew Xiuxuan Zhu et al. · JAMA Oncology Open access 23 Sep 2021 503
24 Functional genomic landscape of cancer-intrinsic evasion of killing by T cells Keith A. Lawson et al. · Nature Open access 23 Sep 2020 488
25 Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer Supriya Kumar Saha et al. · Nature Open access Jul 2014 477
26 AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations Katharine E. Yen et al. · Cancer Discovery 13 Feb 2017 471
27 MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis Katya Marjon, Michael J. Cameron, Phong Quang et al. · Cell Reports Open access Apr 2016 469
28 Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers Janeta V. Popovici-Müller et al. · ACS Medicinal Chemistry Letters Open access 19 Jan 2018 454
29 Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2 Maria Fernanda Amary, Stephen Damato, Dina Halai et al. · Nature Genetics 6 Nov 2011 440
30 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia Rocco Piazza et al. · Nature Genetics Open access 9 Dec 2012 428
31 Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy Ovidiu C. Andronesi, Grace S. Kim, Elizabeth Robins Gerstner et al. · Science Translational Medicine Open access 11 Jan 2012 428
32 Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8+ T Cells Eric H. Ma et al. · Immunity Open access 10 Oct 2019 417
33 Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism Tao Xu, Kelly M. Stewart, Xiaohu Wang et al. · Nature Open access Aug 2017 403
34 Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia Gail J. Roboz et al. · Blood Open access 16 Dec 2019 384
35 IDH mutations in glioma and acute myeloid leukemia Lenny Dang, Shengfang Jin, Shin-San Michael Su · Trends in Molecular Medicine Review 6 Aug 2010 377
36 Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Michael D. Amatangelo, Lynn Swun Quek, Alan H. Shih et al. · Blood Open access 6 Jun 2017 365
37 Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming Dominic Guy Roy et al. · Cell Metabolism Open access Feb 2020 357
38 Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages Amanda Swain, Monika Bambousková, Hyeryun Kim et al. · Nature Metabolism Open access 25 May 2020 340
39 Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib Eytan M. Stein et al. · Blood Open access 4 Dec 2018 337
40 Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy Whitney B. Pope et al. · Journal of Neuro-Oncology Open access 20 Oct 2011 326
41 Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma Ingo K. Mellinghoff et al. · Journal of Clinical Oncology Open access 12 Jun 2020 322
42 The mitochondrial respiratory chain is essential for haematopoietic stem cell function Elena Ansó, Samuel Edward Weinberg, Lauren P. Diebold et al. · Nature Cell Biology Open access 15 May 2017 322
43 Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML Courtney Denton Dinardo, Farhad Ravandi, Sam Agresta et al. · American Journal of Hematology Open access 28 May 2015 320
44 Cancer-associated IDH mutations: biomarker and therapeutic opportunities Katharine E. Yen, M. Bittinger, Shin-San Michael Su et al. · Oncogene 25 Oct 2010 302
45 D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function Masato Sasaki, Christiane Brigitte Knobbe-Thomsen, Momoe Itsumi et al. · Genes & Development Open access 27 Aug 2012 300
46 Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations Andrew M. Intlekofer et al. · Nature Open access 27 Jun 2018 285
47 Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial Ingo K. Mellinghoff et al. · Clinical Cancer Research Open access 2 Jun 2021 275
48 MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage Peter Kalev et al. · Cancer Cell Open access 14 Jan 2021 253
49 Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia Daniel Aaron Pollyea, Martin S. Tallman, Stéphane de Botton et al. · Leukemia Open access 9 Apr 2019 252
50 Itaconate confers tolerance to late NLRP3 inflammasome activation Monika Bambousková et al. · Cell Reports Open access Mar 2021 245

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.